BIOL PSYCHIATRY
1990;28:1091–1101

Author Index for Volume 28

Abbott RM. *See* Cosgriff JP
Abe K. *See* Terao T
Abraha A. *See* de Freitas DM
Adesanya T. *See* de Lacoste M-C
Adinoff B. *See* Roy A
Ahlenius S. *See* Wadenberg M-L
Alarcon RD. *See* Tolbert LC
Albert ED. *See* Schreiber W
Alessi N. *See* Shain BN
Allen JS, Matsunaga K, Hacisalihzade S, Stark L. Smooth Pursuit Eye Movements of Normal and Schizophrenic Subjects Tracking an Unpredictable Target, 705
Alosachie I, Peter JB, Tsuchihashi H, Knight DL, Nemeroff CB. Is Decreased Imipramine Binding by Platelet Membranes in Major Depression Associated with Plasma Autoantibodies to Imipramine Binding Sites?, 365
Ameli R. *See* Grillon C
Amsterdam JD, Maislin G. Comparison of Growth Hormone Response After Clonidine and Insulin Hypoglycemia in Affective Illness, 308
Anderson J. *See* McGee R
Arai H. *See* Yamamoto K
Arana GW, Zarzar MN, Baker E. The Effect of Diagnostic Methodology on the Sensitivity of the TRH Stimulation Test for Depression: A Literature Review, 733
Asnis GM. *See* Kalus O
Asnis GM. *See* Kahn RS
Auriacombe M, Tignol J, Le Moal M, Stinus L. Transcutaneous Electrical Stimulation with Limoge Current Potentiates Morphine Analgesia and Attenuates Opiate Abstinence Syndrome, 650
Baker E. *See* Arana GW
Baker GB. *See* Sherry RL
Baker HF. *See* Ridley RM
Ball P. *See* Banger M
Ball WA. *See* Ross RJ
Balon R. *See* Pohl R
Banger M, Hiemke C, Knuppen R, Ball P, Haupt M, Wiedemann K. Formation and Metabolism of Catecholestrogens in Depressed Patients, 685
Barry S. *See* Dinan TG
Bartko JJ. *See* Wolkowitz OM
Bartzokis G, Garber HJ, Marder SR, Olendorf WH. MRI in Tardive Dyskinesia: Shortened Left Caudate T_2, 1027
Baumgartner A, Gräf K-R, Kürten I, Meinhold H, Scholz P. Neuroendocrinological Investigations During Sleep Deprivation in Depression: I. Early Morning Levels of Thyrotropin, TH, Cortisol, Prolactin, LH, FSH, Estradiol, and Testosterone, 556
Baumgartner A, Riemann D, Berger M. Neuroendocrinological Investigations During Sleep Deprivation in Depression: II. Longitudinal Measurement of Thyrotropin, TH, Cortisol, Prolactin, GH, and LH During Sleep and Sleep Deprivation, 569
Beccaria L. *See* Wolkowitz OM
Berger M. *See* Baumgartner A
Berman W. *See* Decina P
Berrios GE. *See* Dening TR
Bidder M, Ratzoni G, Weizman A, Blumensohn R, Norymberg M, Tyano S, Gavish M. Platelet Benzodiazepine Binding in Alzheimer's Disease, 641
Biederman J. *See* Steingard R
Bigelow LB. *See* Casanova MF
Biondi F, Di Rubbo R, Faravelli C, Mannaioni PF. Chronic Amineptine Abuse, 1004
Bissette G. *See* Roy A
Black D. *See* Pfohl B
Blecha H-G. *See* Schwitzer J
Blum N. *See* Garvey M

Abbreviations:
ed: Editorial
le: Letter to the Editor

© 1990 Society of Biomedical Psychiatry

0006-3223/90/$03.50

Blum N. *See* Pfohl B
Blumensohn R. *See* Bidder M
Boyko OB. *See* Breitner JCS
Boyko OB. *See* Doraiswamy PM
Bracha HS. *See* Lohr JB
Breitner JCS, Husain MM, Figiel GS, Krishnan KRR, Boyko OB. Cerebral White Matter Disease in Late-Onset Paranoid Psychosis, 266
Brewerton TD. *See* Jimerson DC
Brizer D. *See* Volavka J
Brodie JD. *See* Logan J
Brown I. *See* Dinan TG
Bruder G. *See* Towey J
Bruton C. *See* Roberts GW
Buysse DJ, Jarrett DB, Miewald JM, Kupfer DJ, Greenhouse JB. Minute-by-Minute Analysis of REM Sleep Timing in Major Depression, 911
Buysse DJ. *See* Reynolds CF III
Buzina R. *See* Subotičanec K

Cadet JL, Perumal AS. Chronic Treatment With Prolixin Causes Oxidative Stress in Rat Brain, 738
Cairns J. *See* Southmayd SE
Callaway E. *See* Mongan L
Cameron OG, Smith CB, Lee MA, Hollingsworth PJ, Hill EM, Curtis GC. Adrenergic Status in Anxiety Disorders: Platelet Alpha$_2$-Adrenergic Receptor Binding, Blood Pressure, Pulse, and Plasma Catecholamines in Panic and Generalized Anxiety Disorder Patients and in Normal Subjects, 3
Caracci G. *See* Decina P
Carroll BJ. *See* Krishnan KRR
Carroll BT. *See* Pitts AF
Casanova MF, Zito M, Goldberg TE, Suddath RL, Torrey EF, Bigelow LB, Sanders RD, Weinberger DR. Corpus Callosum Curvature in Schizophrenic Twins, 83-le
Cearnal LR. *See* El-Mallakh RS
Chakravarti A. *See* Neiswanger K
Chamberlain RS, Herman BH. A Novel Biochemical Model Linking Dysfunctions in Brain Melatonin, Proopiomelanocortin, Peptides, and Serotonin in Autism, 773
Chatelain F. *See* Massol J
Chee K. *See* Sachdev P
Cheetham SC. *See* Lawrence KM
Coble PA. *See* Reynolds CF III
Coffey CE. *See* Webb MC
Convit A. *See* Volavka J
Cook B. *See* Garvey M
Cooper MD. *See* Luchins DJ
Coryell WH. *See* Miller DD
Cosgriff JP, Abbott RM, Oakley–Browne MA, Joyce PR. Cortisol Hypersecretion Predicts Early Depressive Relapse After Recovery With Electroconvulsive Therapy, 1007
Coutts RT. *See* Sherry RL
Cowdry RW. *See* Gardner DL
Coyle S. *See* Kraiuhin C
Cress MM. *See* Webb MC
Crompton MR. *See* Lawrence KM
Crow TJ. *See* Roberts GW, 127
Crowner M. *See* Volavka J
Csernansky JG. *See* Jibson M
Curtis GC. *See* Cameron OG

Das I. *See* Essali MA
David MM. *See* Southmayd SE
Davies HD. *See* Warner MD
Davis JM. *See* Pandey GN
Davis KL. The Annual Meeting of the Society of Biological Psychiatry: President's Message, 929-ed
Davis KL. *See* Zemishlany Z
de Belleroche J. *See* Essali MA
de Freitas DM, Silberberg J, Espanol MT, Dorus E, Abraha A, Dorus W, Elenz E, Whang W. Measurement of Lithium Transport in RBC from Psychiatric Patients Receiving Lithium Carbonate and Normal Individuals by ^{7}Li NMR Spectroscopy, 415
de Lacoste M-C, Adesanya T, Woodward DJ. Measures of Gender Differences in the Human Brain and Their Relationship to Brain Weight, 931
De Paermentier F. *See* Lawrence KM
De Souza EB. *See* McLeod DR
De Veaugh–Geiss. *See* Katz RJ
de Wolff FA. *See* Van Kempen GMJ
Decina P, Caracci G, Sandik R, Berman W, Mukherjee S, Scapicchio P. Cigarette Smoking and Neuroleptic-Induced Parkinsonism, 502
DeJong J. *See* Roy A
Delva NJ. *See* Southmayd SE
Dement WC. *See* Nishino S

Dening TR, Berrios GE. Wilson's Disease: A Longitudinal Study of Psychiatric Symptoms, 255
Desai B. *See* Domino LE
De Veaugh–Geiss J. *See* Katz RJ
Dinan TG, Barry S, Yatham LN, Mobayed M, Brown I. A Pilot Study of a Neuroendocrine Test Battery in Posttraumatic Stress Disorder, 665
Disselkamp–Tietze J. *See* Lesch KP
Domino LE, Desai B. Diagnosis of Depression in Alcoholics, 84-le
Done DJ. *See* Roberts GW
Doraiswamy PM, Krishnan KRR, Figiel GS, Husain MM, Boyko OB, Rockwell WJK, Ellinwood EH Jr. A Brain Magnetic Resonance Imaging Study of Pituitary Gland Morphology in Anorexia Nervosa and Bulimia, 110
Dorus E. *See* de Freitas DM
Dorus W. *See* de Freitas DM
Duncan CC. *See* Gaist PA
Dysken MW, Falk A, Pew B, Kuskowski M, Krahn DD. Gender Differences in TRH-Stimulated TSH and Prolactin in Primary Degenerative Dementia and Elderly Controls, 144
Dysken MW, Nelson MJ, Maxwell Hoover K, Kuskowski M, McGeachie R. Rapid Dynamic CT Scanning in Primary Degenerative Dementia and Age-Matched Controls, 425

Early TS. Assymetric Metabolism over Basal Ganglia in Catatonia, 177-le
Ebmeier KP, Potter DD, Salzen EA. Filter Frequency in P_3 Experiments, 1071-le (response)
Edelbroek PM. *See* Van Kempen GMJ
El-Mallakh RS, Cearnal LR, Kirch DR. Stereotypic Behavior and Hyponatremia, 1077-le
Elenz E. *See* de Freitas DM
Ellinwood EH Jr. *See* Doraiswamy PM
Ellis J, Lenox RH. Chronic Lithium Treatment Prevents Atropine-Induced Supersensitivity of the Muscarinic Phosphoinositide Response in Rat Hippocampus, 609
Emrich HE. *See* Schreiber W
Engel RR. *See* Kathmann N
Erhan H. *See* Towey J
Ericson E. *See* Wadenberg M-L
Espanol MT. *See* de Freitas DM
Essali MA, Das I, de Belleroche J, Hirsch SR. The Platelet Polyphosphoinositide System in Schizophrenia: The Effects of Neuroleptic Treatment, 475

Fairbairn AF. *See* Leake A
Falk A. *See* Dysken MW
Faull KF. *See* Jibson M
Fekkes D. *See* Klompenhouwer J-L
Ferrier IN. *See* Leake A
Ferris SH. *See* Serby M
Figiel GS. *See* Breitner JCS
Figiel GS. *See* Doraiswamy PM
Fischette C. *See* Hamik A
Fleischhacker WW. *See* Schwitzer J
Flicker C. *See* Serby M
Folnegović–Šmalc V. *See* Subotičanec K
Ford JM. *See* Pfefferbaum A
Fowler JS. *See* Logan J
Frank E. *See* Reynolds CF III
Frank E. *See* Neiswanger K
Frankel DR. *See* Neiswanger K
Freedman R. Evoked Response to Repeated Auditory Stimuli, 1065-le
Freese TE. *See* Satterfield JH
Friedman D. *See* Towey J
Fukui S. *See* Iyo M
Fukushima J, Fukushima K, Morita N, Yamashita I. Further Analysis of the Control of Voluntary Saccadic Eye Movements in Schizophrenic Patients, 943
Fukushima K. *See* Fukushima J

Gaist PA, Obarzanek E, Skwerer RG, Duncan CC, Schultz PM, Rosenthal NE. Effects of Bright Light on Resting Metabolic Rate in Patients With Seasonal Affective Disorder and Control Subjects, 989
Galin D, Rodgers V, Merrin EL. Story Recall Under Monoaural and Binaural Conditions in Psychiatric Patients, 794
Garber HJ. *See* Bartzokis G
Gardner DL, Lucas PB, Cowdry RW. CSF Metabolites in Borderline Personality Disorder Compared with Normal Controls, 247
Garfinkel PE. *See* Goldbloom DS
Garvey M, Cook B, Noyes R Jr, Blum N.

Psychiatric Family History and Urinary MHPG in Healthy Control Subjects, 174
Gattaz WF, Hübner CvK, Nevalainen TJ, Thuren T, Kinnunen PKJ. Increased Serum Phospholipase A_2 Activity in Schizophrenia: a Replication Study, 495
Gavish M. *See* Bidder M
Gehris TL. *See* Pitts AF
Geisler P. *See* Schreiber W
Gertz B. *See* Wolkowitz OM
Giles DE, Roffwarg HP, Rush AJ. A Cross-Sectional Study of the Effects of Depression on REM Latency, 697
Giller E Jr. *See* Kosten TR
Glazer WM. *See* Grillon C
Goekoop JG. *See* Van Kempen GMJ
Goetz RR. *See* Gorman JM
Goldberg TE. *See* Casanova MF
Goldbloom DS. *See* Halaman M
Goldbloom DS, Hicks LK, Garfinkel PE. Platelet Serotonin Uptake in Bulimia Nervosa, 644
Gordon E. *See* Kraiuhin C
Gorman JM, Papp LA, Martinez J, Goetz RR, Hollander E, Liebowitz MR, Jordan F. High-Dose Carbon Dioxide Challenge Test in Anxiety Disorder Patients, 743
Gräf K-R. *See* Baumgartner A
Greden JF. *See* Panzer M
Greenhouse JB. *See* Buysse DJ
Gresch PJ. *See* Ross RJ
Grillon C, Ameli R, Glazer WM. Brainstem Auditory-Evoked Potentials to Different Rates and Intensities of Stimulation in Schizophrenics, 819
Gurguis GNM, Uhde TW. Effect of Yohimbine on Plasma Homovanillic Acid in Panic Disorder Patients and Normal Controls, 292
Guze ST. The Scope of Biological Psychiatry, 741-ed

Hacisalihzade S. *See* Allen JS
Hagimoto H. *See* Miyauchi T
Halbreich U. Estrogen Replacement in Postmenopausal Disorders, 369-ed
Halbreich U. Theory and Practice, 649-ed
Halman M, Goldbloom DS. Fluoxetine and Neuroleptic Malignant Syndrome, 518
Hamik A, Oksenberg D, Fischette C, Peroutka SJ. Analysis of Tandospirone (SM-3997) Interactions with Neurotransmitter Receptor Binding Sites, 99
Hards RG. *See* Zemishlany Z
Harris D. *See* Menza MA
Hashimoto R, Ozaki N, Ohta T, Kasahara Y, Kaneda N, Nagatsu T. The Plasma Tetrahydrobiopterin Levels in Patients with Affective Disorders, 526
Hauger RL. *See* Rausch JL
Haupt M. *See* Banger M
Hayaishi O. *See* Nishino S
Hegg AP. *See* Jimerson DC
Herman BH. *See* Chamberlain RS
Hicks LK. *See* Goldbloom DS
Hiemke C. *See* Banger M
Hill EM. *See* Cameron OG
Hirsch SR. *See* Essali MA
Hoch CC. *See* Reynolds CF III
Hoehn–Saric R. *See* McLeod DR
Hoh A. *See* Lesch KP
Hollander E. *See* Gorman JM
Hollander E. *See* Towey J
Hollingsworth PJ. *See* Cameron OG
Hommer D. *See* Lucas PB
Horton RW. *See* Lawrence KM
Houck PR. *See* Reynolds CF III
Howson A. *See* Kraiuhin C
Hübner CvK. *See* Gattaz WF
Hughes HB. *See* Neiswanger K
Husain MM. *See* Breitner JCS
Husain MM. *See* Doraiswamy PM

Ionescu G, Kiehl R, Ona L, Wichmann–Kunz F. Abnormal Plasma Catecholamines in Hyperkinetic Children, 547
Itoh T. *See* Iyo M
Iyo M, Itoh T, Yamasaki T, Fukui S. D_2 Receptor Occupancy and Plasma Concentration of Antipsychotics, 1067-le

Jacobs M-P. *See* Maes M
Janicak PG. *See* Pandey GN
Jarrett DB. *See* Buysse DJ
Jarrett DB. *See* Reynolds CF III
Jeste DV. *See* Lohr JB
Jibson M, Faull KF, Csernansky JG. Intercorrelations Among Monoamine Metabolite Concentrations in Human Lumbar CSF Are Not Due to a Shared Acid Transport System, 595
Jimerson DC, Lesem MD, Kaye WH, Hegg AP,

Brewerton TD. Eating Disorders and Depression: Is There a Serotonin Connection?, 443
Jong HB. *See* Van Kempen GM
Jordan F. *See* Gorman JM
Joyce PR. *See* Cosgriff JP

Kahn RS. *See* Kalus O
Kahn RS, Wetzler S, Asnis GM, Papolos D, van Praag HM. Serotonin Receptor Sensitivity in Major Depression, 358
Kalkstein D. *See* Serby M
Kalus O, Kahn RS, Wetzler S, Asnis GM, van Praag HM. Hypersensitivity to *m*-Chlorophenylpiperazine in a Subject With Subclinical Panic Attacks, 1053
Kaneda N. *See* Hashimoto R
Kaplan BB. *See* Neiswanger K
Kasahara Y. *See* Hashimoto R
Kathmann N, Engel RR Evoked Response to Repeated Auditory Stimuli, 1066-le (response)
Kathol R. *See* Williams JW Jr
Kathol RG. *See* Pitts AF
Katona CLE. *See* Lawrence KM
Katz RJ, De Veaugh–Geiss J, Landau P. Clomipramine in Obsessive-Compulsive Disorder, 401
Katz RJ, Landau P, De Veaugh–Geiss. Drug Versus Behavioral Treatment of Obsessive-Compulsive Disorder (response), 1073-le
Kawakatsu S, Morinobu S, Shinohara M, Totsuka S, Kobashi K. Acetylcholinesterase Activities and Monoamine Metabolite Levels in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, 387
Kay SR. *See* Merriam AE
Kaye WH. *See* Jimerson DC
Keck PE Jr, Seeler DC, Pope HG Jr, McElroy SL. Porcine Stress Syndrome: An Animal Model for the Neuroleptic Malignant Syndrome?, 58
Keenan K. *See* Steingard R
Kelley M. *See* Pfohl B
Kelly MW. *See* Miller DD
Kelsoe J. *See* Lucas PB
Kiehl R. *See* Ionescu G
Kilduff TS. *See* Nishino S
Kinnunen PKJ. *See* Gattaz WF
Kirch DR. *See* El-Mallakh RS
Kishimoto H. *See* Miyauchi T
Klockhoff I. *See* Lindström LH
Klompenhouwer J-L, Fekkes D, van Hulst AM, Moleman P, Pepplinkhuizen L, Mulder PGH. Seasonal Variations in Binding of ^{3}H-Paroxetine to Blood Platelets in Healthy Volunteers: Indications for a Gender Difference, 509
Knight A. *See* Knight JG
Knight DL. *See* Alosachie I
Knight JG, Knight A, Menkes DB, Mullen PE. Autoantibodies Against Brain Septal Region Antigens Specific to Unmedicated Schizophrenia?, 467
Knuppen R. *See* Banger M
Kobashi K. *See* Kawakatsu S
Korbar M. *See* Subotičanec K
Kosten TR, Wahby V, Giller E Jr, Mason J. The Dexamethasone Suppression Test and Thyrotropin-Releasing Hormone Stimulation Test in Posttraumatic Stress Disorder, 657
Krahn DD. *See* Dysken MW
Kraiuhin C, Gordon E, Soyle S, Sara G, Rennie C, Howson A, Landau P, Meares R. Normal Latency of the P300 Event-Related Potential in Mild-to-Moderate Alzheimer's Disease and Depression, 372
Krieg JC. *See* Schreiber W
Krishnan KRR, Ritchie JC, Saunders W, Wilson W, Nemeroff CB, Carroll BJ. Nocturnal and Early Morning Secretion of ACTH and Cortisol in Humans, 47
Krishnan KRR. *See* Breitner JCS
Krishnan KRR. *See* Doraiswamy PM
Kuczenski R. *See* Lohr JB
Kupfer DJ. *See* Buysse DJ
Kupfer DJ. *See* Reynolds CF III
Kupfer DJ. *See* Neiswanger K
Kürten I. *See* Baumgartner A
Kushner SF. *See* Merriam AE
Kuskowski M. *See* Dysken MW

Landau P. *See* Katz RJ
Landau P. *See* Kraiuhin C
Lapin IP. Beta-Phenylethylamine (PEA): An Endogenous Anxiogen?, 997
Larson P. *See* Serby M
Lauer CJ. *See* Schreiber W
Lawlor BA. *See* Mellow AM
Lawrence KM, De Paermentier F, Cheetham SC,

Crompton MR, Katona CLE, Horton RW. Symmetrical Hemispheric Distribution of ^{3}H-Paroxetine Binding Sites in Postmortem Human Brain from Controls and Suicides, 544
Lazarus A. EPS, NMS, and AIDS, 551-le
Le Moal M. *See* Auriacombe M
Leadbetter RA. *See* Vieweg VWR
Leake A, Perry EK, Perry RH, Fairbairn AF, Ferrier IN. Cortical Concentrations of Corticotropin-Releasing Hormone and Its Receptor in Alzheimer Type Dementia and Major Depression, 603
Lee MA. *See* Cameron OG
Lenox RH. *See* Ellis J
Lepola U, Nousiainen U, Puranen M, Riekkinen P, Rimón R. EEG and CT Findings in Patients With Panic Disorder, 721
Lesch KP, Mayer S, Disselkamp–Tietze J, Hoh A, Wiesmann M, Osterheider M, Schulte HM. 5-HT_{1A} Receptor Responsivity in Unipolar Depression: Evaluation of Ipsapirone-Induced ACTH and Cortisol Secretion in Patients and Controls, 620
Lesem MD. *See* Jimerson DC
Letemendia FJ. *See* Southmayd SE
Liddle RA. *See* Wolkowitz OM
Liebowitz M. *See* Towey J
Liebowitz MR. *See* Gorman JM
Lindström LH, Wieselgren I-M, Klockhoff I, Svedberg A. Relationship Between Abnormal Brainstem Auditory-Evoked Potentials and Subnormal CSF Levels of HVA and 5-HIAA in First-Episode Schizophrenic Patients, 435
Linnoila M. *See* Roy A
Lo CW. Excitatory Amino Acids and Schizophrenia, 552-le
Logan J, Schlyer DJ, Wolf AP, Fowler JS, Brodie JD. D_2 Receptor Occupancy and Plasma Concentration of Antipsychotics, 1068-le (response)
Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. Increased Indices of Free Radical Activity in the Cerebrospinal Fluid of Patients with Tardive Dyskinesia, 535
Lucas PB. *See* Gardner DL
Lucas PB, Pickar D, Kelsoe J, Rapaport M, Pato C, Hommer D. Effects of the Acute Administration of Caffeine in Patients with Schizophrenia, 35
Luchins DJ, Metz JT, Marks RC, Cooper MD. Assymetric Metabolism over Basal Ganglia in Catatonia, 177-le (response)
Luchins DJ. A Possible Role of Hippocampal Dysfunction in Schizophrenic Symptomatology, 87

Maes M, Jacobs M-P, Suy E, Minner B, Raus J. Prediction of the DST Results in Depressives by Means of Urinary-Free Cortisol Excretion, Dexamethasone Levels, and Age, 349
Magnusson O. *See* Wadenberg M-L
Maislin G. *See* Amsterdam JD
Marder SR. *See* Bartzokis G
Marks I. Drug Versus Behavioral Treatment of Obsessive-Compulsive Disorder, 1072-le
Marks RC. *See* Luchins DJ
Marks RC. *See* Pandey GN
Martin P. *See* Massol J
Martinez J. *See* Gorman JM
Mason J. *See* Kosten TR
Massol J, Martin P, Chatelain F, Puech AJ. Tricyclic Antidepressants, Thyroid Function, and Their Relationship With the Behavioral Responses in Rats, 967
Matsunaga K. *See* Allen JS
Matsushita M. *See* Miyauchi T
Maxwell Hoover K. *See* Dysken MW
Mayer S. *See* Lesch KP
McAfee B. *See* Teoh SK
McCarty MJ. *See* Neiswanger K
McElroy SL. *See* Keck PE Jr
McElroy SL. *See* Teoh SK
McGeachie R. *See* Dysken MW
McGee R, Williams S, Anderson J, McKenzie-Parnell JM, Silva PA. Hyperactivity and Serum and Hair Zinc Levels in 11-Year-Old Children from the General Population, 165
McKenzie-Parnell JM. *See* McGee R
McLeod DR, Hoehn–Saric R, Zimmerli WD, De Souza EB, Oliver LK. Treatment Effects of Alprazolam and Imipramine: Physiological Versus Subjective Changes in Patients With Generalized Anxiety Disorder, 849
McLeod WR. *See* Sitaram BR
Meares R. *See* Kraiuhin C
Meinhold H. *See* Baumgartner A
Mellerup ET, Plenge P. The Side Effects of

Lithium, 464-ed
Mello NK. *See* Teoh SK
Mellow AM, Lawlor BA, Sunderland T, Mueller EA, Molchan SE, Murphy DL. Effects of Daily Oral *m*-Chlorophenylpiperazine in Elderly Depressed Patients: Initial Experience with a Serotonin Agonist, 588
Mendelson JH. *See* Teoh SK
Menkes DB. *See* Knight JG
Menza MA, Harris D. Benzodiazepines and Catatonia, 179-le (response)
Merriam AE, Kay SR, Opler LA, Kushner SF, van Praag HM. Neurological Signs and the Positive-Negative Dimension in Schizophrenia, 181
Merrin EL. *See* Galin D
Meštrović B. *See* Subotičanec K
Metz JT. *See* Luchins DJ
Miewald JM. *See* Buysse DJ
Mignot E. *See* Nishino S
Miller DD, Kelly MW, Perry PJ, Coryell WH. The Influence of Cigarette Smoking on Haloperidol Pharmacokinetics, 529
Minkoff JR. *See* Warner MD
Minner B. *See* Maes M
Mitchell P, Smythe G, Torda T. Effect of the Anesthetic Agent Propofol on Hormonal Responses to ECT, 315
Miura T. *See* Miyauchi T
Miyauchi T, Tanaka T, Hagimoto H, Miura T, Kishimoto H, Matsushita M. Computerized EEG in Schizophrenic Patients, 488
Mobayed M. *See* Dinan TG
Moir M. *See* Lohr JB
Molchan SE. *See* Mellow AM
Moleman P. *See* Klompenhouwer J-L
Mongan L, Callaway E. Buprenorphine Responders, 1078-le
Moore C. *See* Steingard R
Moore–Ede MC. *See* Welsh DK
Morinobu S. *See* Kawakatsu S
Morita N. *See* Fukushima J
Morrison AR. *See* Ross RJ
Moss HB, Yao JK, Panzak GL. Serotonergic Responsivity and Behavioral Dimensions in Antisocial Personality Disorder with Substance Abuse, 325
Mueller EA. *See* Mellow AM
Mukherjee S. *See* Decina P
Mulder PGH. *See* Klompenhouwer J-L
Mullen PE. *See* Knight JG
Murphy DL. *See* Mellow AM
Muscat R, Sampson D, Willner P. Dopaminergic Mechanism of Imipramine Action in an Animal Model of Depression, 223
Mutgi A. *See* Williams JW Jr

Nagatsu T. *See* Hashimoto R
Nakayama S. *See* Yamamoto K
Naylor M. *See* Shain BN
Naylor MW, Shain BN, Shipley JE. REM Latency in Psychotically Depressed Adolescents, 161
Neiswanger K, Slaugenhaupt SA, Hughes HB, Frank E, Frankel DR, McCarty MJ, Chakravarti A, Zubenko GS, Kupfer DJ, Kaplan BB. Evidence Against Close Linkage of Unipolar Affective Illness to Human Chromosome 11p Markers HRAS1 and INS and Chromosome Xq Marker DXS52, 63
Nelson MJ. *See* Dysken MW
Nemeroff CB. *See* Roy A
Nemeroff CB. *See* Alosachie I
Nemeroff CB. *See* Krishnan KRR
Neudorfer C. *See* Schwitzer J
Nevalainen TJ. *See* Gattaz WF
Nicholas TW. *See* Satterfield JH
Nishino S, Mignot E, Kilduff TS, Sakai T, Hayaishi O, Dement WC. Prostaglandin E_2 Levels in Cerebrospinal Fluid of Normal and Narcoleptic Dogs, 904
Norymberg M. *See* Bidder M
Nousiainen U. *See* Lepola U
Noyes R Jr. *See* Garvey M
Noyes R Jr. *See* Pfohl B
Noyes R Jr. *See* Williams JW Jr

Oakley–Browne MA. *See* Cosgriff JP
Obarzanek E. *See* Gaist PA
Ohta T. *See* Hashimoto R
Oksenberg D. *See* Hamik A
Olendorf WH. *See* Bartzokis G
Oliver LK. *See* McLeod DR
Olney JW. Excitatory Amino Acids and Schizophrenia, 553-le (response)
Ona L. *See* Ionescu G
Opler LA. *See* Merriam AE
Osterheider M. *See* Lesch KP
Ozaki N. *See* Hashimoto R

Pandey GN, Pandey SC, Janicak PG, Marks RC,

Davis JM. Platelet Serotonin-2 Receptor Binding Sites in Depression and Suicide, 215
Pandey SC. *See* Pandey GN
Panzak GL. *See* Moss HB
Panzer M, Tandon R, Greden JF. Benzodiazepines and Catatonia, 178-le
Papolos D. *See* Kahn RS
Papp LA. *See* Gorman JM
Pappas GD. *See* Sagen J
Pato C. *See* Lucas PB
Patterson D. *See* Zemishlany Z
Peabody CA. *See* Warner MD
Pepplinkhuizen L. *See* Klompenhouwer J-L
Peroutka SJ. *See* Hamik A
Perry EK. *See* Leake A
Perry PJ. *See* Miller DD
Perry PJ. *See* Williams JW Jr
Perry RH. *See* Leake A
Perumal AS. *See* Cadet JL
Peter JB. *See* Alosachie I
Pew B. *See* Dysken MW
Pfefferbaum A, Ford JM, Roth WT. Filter Frequency in P_3 Experiments, 1070-le
Pfohl B, Black D, Noyes R Jr, Kelley M, Blum N. A Test of the Tridimensional Personality Theory: Association with Diagnosis and Platelet Imipramine Binding in Obsessive-Compulsive Disorder, 41
Pickar D. *See* Wolkowitz OM
Pickar D. *See* Lucas PB
Pitts AF, Carroll BT, Gehris TL, Kathol RG, Samuelson SD. Elevated CSF Protein in Male Patients with Depression, 629
Plenge P. *See* Mellerup ET
Pohl R, Yeregani VK, Balon R. Effects of Isoproterenol in Panic Disorder Patients After Antidepressant Treatment, 203
Pollmächer T. *See* Schreiber W
Pope HG Jr. *See* Keck PE Jr
Potter DD. *See* Ebmeier KP
Puech AJ. *See* Massol J
Puranen M. *See* Lepola U

Rapaport M. *See* Lucas PB
Ratzoni G. *See* Bidder M
Raus J. *See* Maes M
Rausch JL, Stahl SM, Hauger RL. Cortisol and Growth Hormone Responses to the 5-HT1A Agonist Gepirone in Depressed Patients, 73
Ravitz B. *See* Roy A
Rennie C. *See* Kraiuhin C
Reynolds CF III, Kupfer DJ, Thase ME, Frank E, Jarrett DB, Coble PA, Hoch CC, Buysse DJ, Simons AD, Houck PR.Sleep, Gender, and Depression: An Analysis of Gender Effects on the Electroencephalographic Sleep of 302 Depressed Outpatients, 673
Ridley RM, Baker HF. Implications of Age of Onset for the Genetics of Schizophrenia, 455
Riekkinen P. *See* Lepola U
Riemann D. *See* Baumgartner A
Riemann D. *See* Schreiber W
Rimón R. *See* Lepola U
Ritchie JC. *See* Krishnan KRR
Roberts GW, Done DJ, Bruton C, Crow TJ. A "Mock Up" of Schizophrenia: Temporal Lobe Epilepsy and Schizophrenia-Like Psychosis, 127
Rockwell WJK. *See* Doraiswamy PM
Rodgers V. *See* Galin D
Roemer RA, Shagass C. Replication of an Evoked Potential Study of Lateralized Hemispheric Dysfunction in Schizophrenics, 275
Roffwarg HP. *See* Giles DE
Rosenthal NE. *See* Gaist PA
Ross RJ, Ball WA, Gresch PJ, Morrison AR. REM Sleep Suppression by Monoamine Reuptake Blockade: Development of Tolerance with Repeated Drug Administration, 231
Roth WT. *See* Pfefferbaum A
Rotrosen JP. *See* Serby M
Roy A, Bissette G, Nemeroff CB, DeJong J, Ravitz B, Adinoff B, Linnoila M. Cerebrospinal Fluid Thyrotropin-Releasing Hormone Concentrations in Alcoholics and Normal Controls, 767
Rush AJ. *See* Giles DE
Ryan WG. *See* Tolbert LC
Rypma B. *See* Serby M

Sachdev P, Chee K. Pharmacological Characterization of Tardive Akathisia, 809
Sagen J, Sortwell CE, Pappas GD. Monoaminergic Neural Transplants Prevent Learned Helplessness in a Rat Depression Model, 1037
Sakai T. *See* Nishino S
Salzen EA. *See* Ebmeier KP
Sampson D. *See* Muscat R
Samuelson SD. *See* Pitts AF

Sanders RD. *See* Casanova MF
Sandik R. *See* Decina P
Sapolsky RM. Adrencortical Function, Social Rank, and Personality Among Wild Baboons, 862
Sara G. *See* Kraiuhin C
Satterfield BT. *See* Satterfield JH
Satterfield JH, Schell AM, Nicholas TW, Satterfield BT, Freese TE. Ontogeny of Selective Attention Effects on Event-Related Potentials in Attention-Deficit Hyperactivity Disorder and Normal Boys, 879
Saunders WR. *See* Krishnan KRR
Saunders WR. *See* Webb MC
Scapicchio P. *See* Decina P
Schell AM. *See* Satterfield JH
Schlyer DJ. *See* Logan J
Scholz P. *See* Baumgartner A
Scholz S. *See* Schreiber W
Schreiber W, Schulz H, Lauer CJ, Geisler P, Pollmächer T, Scholz S, Krieg JC, Wiegand M, Riemann D, Emrich HE, Albert ED. HLA-DR2 and Sleep Onset REM Periods in Depression, 1012-le
Schulte HM. *See* Lesch KP
Schultz PM. *See* Gaist PA
Schulz H. *See* Schreiber W
Schwitzer J, Neudorfer C, Blecha H-G, Fleischhacker WW. Mania as a Side Effect of Phototherapy, 532
Sebastian CS. Water Intoxication Treatment, 829-le (response)
Seeler DC. *See* Keck PE Jr
Serby M, Flicker C, Rypma B, Weber S, Rotrosen JP, Ferris SH. Scopolamine and Olfactory Function, 79
Serby M, Larson P, Kalkstein D. Olfactory Sense in Psychoses, 830-le
Shagass C. *See* Roemer RA
Shain BN, Naylor M, Shipley JE, Alessi N. Imipramine Effects on Sleep in Depressed Adolescents: A Preliminary Report, 459
Shain BN. *See* Naylor MW
Sherry RL, Baker GB, Coutts RT. Effects of Low-Dose 4-Fluorotrancylcypromine on Rat Brain Monoamine Oxidase and Neurotransmitter Amines, 539
Sherwin BB, Suranyi–Cadotte BE. Up-Regulatory Effect of Estrogen on Platelet ^{3}H-Imipramine Binding Sites in Surgically Menopausal Women, 339
Shinohara M. *See* Kawakatsu S
Shipley JE. *See* Naylor MW
Shipley JE. *See* Shain BN
Sibert TR. *See* Webb MC
Silberberg J. *See* de Freitas DM
Silva PA. *See* McGee R
Simons AD. *See* Reynolds CF III
Sitaram BR, McLeod WR. Observations of the Metabolism of the Psychomimetic Indolealkylamines: Implications for Future Clinical Studies, 841
Skwerer RG. *See* Gaist PA
Slaugenhaupt SA. *See* Neiswanger K
Smith CB. *See* Cameron OG
Smythe G. *See* Mitchell P
Sortwell CE. *See* Sagen J
Southmayd SE, David MM, Cairns J, Delva NJ, Letemendia FJ, Waldron JJ. Sleep Deprivation in Depression: Pattern of Relapse and Characteristics of Preceding Sleep, 979
Sovner R. Amphetamine and Trancylcypromine in Treatment-Resistant Depression, 1011-le
Stahl SM. *See* Rausch JL
Stark L. *See* Allen JS
Stein MB, Uhde TW. Triiodothyronine Potentiation of Tricyclic Antidepressant Treatment in Patients With Panic Disorder, 1061
Steingard R, Biederman J, Keenan K, Moore C. Comorbidity in the Interpretation of Dexamethasone Suppression Test Results in Children: A Review and Report, 193
Stinus L. *See* Auriacombe M
Subotičanec K, Folnegović–Šmalc V, Korbar M, Meštrović B, Buzina R. Vitamin C Status in Chronic Schizophrenia, 959
Suckow RF. *See* Volavka J
Suddath RL. *See* Casanova MF
Sunderland T. *See* Mellow AM
Suranyi–Cadotte BE. *See* Sherwin BB
Sutton S. *See* Towey J
Suy E. *See* Maes M
Svedberg A. *See* Lindström LH
Szmukler GI. Psychiatry Down Under, 835-ed

Tamminga CA. *See* Thaker GK
Tanaka T. *See* Miyauchi T
Tandon R. *See* Panzer M

Targum SD. Differential Responses to Anxiogenic Challenge Studies in Patients with Major Depressive Disorder and Panic Disorder, 21
Teoh SK, Mendelson JH, Mello NK, Weiss R, McElroy S, McAfee B. Hyperprolactinemia and Risk for Relapse of Cocaine Abuse, 824
Terao T, Yoshimura R, Abe K. Lithium Potentiation of Tetracyclic Antidepressants, 1075-le
Thaker GK, Wagman AMI, Tamminga CA. Sleep Polygraphy in Schizophrenia: Methodological Issues, 240
Thase ME. *See* Reynolds CF III
Thompson K. *See* Wolkowitz OM
Thuren T. *See* Gattaz WF
Tignol J. *See* Auriacombe M
Tolbert LC, Ryan WG, Alarcon RD. Temporal Relationship Between Clinical Changes and MAT Changes Following ECT, 1049
Torda T. *See* Mitchell P
Torrey EF. *See* Casanova MF
Totsuka S. *See* Kawakatsu S
Towey J, Bruder G, Hollander E, Friedman D, Erhan H, Liebowitz M, Sutton S. Endogenous Event-Related Potentials in Obsessive- Compulsive Disorder, 92
Tsuchihashi H. *See* Alosachie I
Turner WJ. Importance of Treatment Follow-up, 554-le
Tyano S. *See* Bidder M

Uhde TW. *See* Gurguis GNM
Uhde TW. *See* Stein MB

van Hulst AM. *See* Klompenhouwer J-L
Van Kempen GMJ, Goekoop JG, Jong HB, Edelbroek PM, de Wolff FA. The Plasma Level of Methylphenidate in the Single-Dose Oral Methylphenidate Test, 638
van Praag HM. *See* Kahn RS
van Praag HM. *See* Merriam AE
van Praag HM. *See* Kalus O
van Praag HM. *See* Volavka J
Vieweg WVR, Leadbetter RA. Water Intoxication Treatment, 829-le
Vinogradov S. *See* Warner MD
Volavka J, Crowner M, Brizer D, Convit A, van Praag H, Suckow RF. Tryptophan Treatment of Aggressive Psychiatric Inpatients, 728

Wadenberg M-L, Ericson E, Magnusson O, Ahlenius S. Suppression of Conditioned Avoidance Behavior by the Local Application of (–)Sulpiride into the Ventral, but not the Dorsal, Striatum of the Rat, 297
Wagman AMI. *See* Thaker GK
Wahby V. *See* Kosten TR
Waldron JJ. *See* Southmayd SE
Warner MD, Vinogradov S, Peabody CA, Widrow L, Davies HD, Minkoff JR, Winograd CH. TRH/LHRH Stimulation Test and Alzheimer's Disease, 362
Webb MC, Coffey CE, Saunders WR, Cress MM, Weiner RD, Sibert TR. Cardiovascular Response to Unilateral Electroconvulsive Therapy, 758
Weber S. *See* Serby M
Weinberger DR. *See* Casanova MF
Weiner RD. *See* Webb MC
Weingartner H. *See* Wolkowitz OM
Weiss R. *See* Teoh SK
Weizman A. *See* Bidder M
Welsh DK, Moore–Ede MC. Lithium Lengthens Circadian Period in a Diurnal Primate: *Saimiri sciureus*, 117
Wetzler S. *See* Kahn RS
Wetzler S. *See* Kalus O
Whang W. *See* de Freitas DM
Wichmann–Kunz F. *See* Ionescu G
Widrow L. *See* Warner MD
Wiedemann K. *See* Banger M
Wiegand M. *See* Schreiber W
Wieselgren I-M. *See* Lindström LH
Wiesmann M. *See* Lesch KP
Williams JW Jr, Mutgi A, Noyes R, Perry P, Kathol R. Comparison of Urinary-Free Cortisol in Depressed and Nondepressed Patients with Malignancy, 522
Williams S. *See* McGee R
Willner P. *See* Muscat R
Wilson W. *See* Krishnan KRR
Winograd CH. *See* Warner MD
Wolf AP. *See* Logan J
Wolkowitz OM, Bartko JJ, Pickar D. Drug Trials and Heterogeneity in Schizophrenia: The Mean is not the End, 1021-ed
Wolkowitz OM, Gertz B, Weingartner H, Beccaria L, Thompson K, Liddle RA. Hunger in Humans Induced by MK-329, a Specific Peripheral-Type Cholecystokinin Receptor

Antagonist, 169
Woodward DJ. *See* de Lacoste M-C
Wortis J. Getting Away With Murder, 555-ed
Wortis J. The Psychiatric Literature: Some Perspectives, 1-ed

Yamamoto K, Arai H, Nakayama S. Skin Conductance Response after 6-Hydroxydopamine Lesion of Central Noradrenaline System in Cats, 151
Yamasaki T. *See* Iyo M
Yamashita I. *See* Fukushima J
Yao JK. *See* Moss HB
Yatham LN. *See* Dinan TG
Yeregani VK. *See* Pohl R
Yoshimura R. *See* Terao T

Zarzar MN. *See* Arana GW
Zemishlany Z, Patterson D, Davis KL, Hards RG. Glycinamide Ribonucleotide Synthetase Activity in Lymphocytes From Patients With Alzheimer's Disease and Normal Controls, 1058
Zimmerli WD. *See* McLeod DR
Zito M. *See* Casanova MF
Zubenko GS. *See* Neiswanger K

Subject Index for Volume 28

Acetylcholine
in olfactory function, 79
Acetylcholinesterase
in Alzheimer's disease, 387
Acid transport system
shared, CSF monoamine metabolite intercorrelations not due to, 595
ACTH. *See* Adrenocorticotropic hormone
Acute dyskinesia
tardive akathisia pathophysiology in relation to, 809
Adenosinergic systems
caffeine effect on, 35
Adenylate cyclase
studies, 5-HT1A receptor-mediated effects assessed via, 99
Adjustment disorder
buprenorphine against, 1079-le
Adolescents
depression in, imipramine effects on sleep in, 459
psychotically depressed, REM latency in, 161
Adrenal medulla
tissue, in monoaminergic neural transplantation, 1037
β-Adrenergic blockers
β-phenylethylamine-induced seizures prevented by, 999
α_2-Adrenergic receptors
platelet, in anxiety disorders, 3
β-Adrenergic receptors
tandospirone activity at, 99
Adrenocorticotropic hormone (ACTH)
in autism, 773
early morning secretion of, 47
ipsapirone induction of, 620
nocturnal secretion of, 47
response in electroconvulsive therapy, propofol effect on, 315
in wild baboons, 862
Affective disorders
chromosome 11p15 markers in, 63
chromosome Xq marker in, 63
circadian rhythms in, 117
growth hormone response abnormalities in, 308
serotonin role in, 588
tetrahydrobiopterin levels in, 526
Age
of onset, in schizophrenia, 455
prediction of dexamethasone suppression test results in depressives via, 349
Aggressive behavior
tryptophan against, 728
Agonists
β-adrenergic, 203
α_2-adrenoreceptor, 999
5-hydroxytryptamine, 588, 1053
Alcoholism
CSF TRH concentrations in, 767
in depression, 84-le
Alderlin
β-phenylethylamine-induced seizures prevented by, 999
Alprazolam
against generalized anxiety disorder, 849
against schizophrenia, 1023-ed
Alzheimer's disease
acetylcholinesterase in, 387
benzodiazepine binding in, 641
Down's syndrome correlated with, 1058
event-related potentials in, 372
corticotropin-releasing hormone receptor in, 603
glycinamide ribonucleotide synthetase activity in, 1058
monoamine metabolites in, 387
olfactory deficits in, 79
TRH/LHRH stimulation test and, 362
Amineptine
addiction to, 1004
Amino acids
against aggressive behavior, 728

Abbreviations:
ed: Editorial
le: Letter to the Editor

excitatory, in schizophrenia, 552-le, 553-le (response)
Amitriptyline
anhedonia reduced by, 224
β-phenylethylamine-induced seizures prevented by, 999
sleep alterations induced by, 459, 981
Amphetamines
abuse of, in depression, 85
tranylcypromine coadministration with, 1011-le
Anesthetic induction agents
electroconvulsive therapy seizure duration reduced by, 315
Anhedonia
in endogenous depression, 224
Animal model
of depression, imipramine action in, 223
for neuroleptic malignant syndrome, 58
Anorexia nervosa
pituitary gland in, 110
serotonin pathways in, 443
Antagonists
α_2-adrenergic, 292
Anticholinergic agents
against catatonia, 178, 179-le (response)
Antidepressants
circadian rhythms lengthened by, 117
dopaminergic mechanism of action of, 223
5-HT1A receptors in action of, 73
isoproterenol infusion after, 203
mania as side effect of, 532
methylphenidate test in prediction of therapeutic response to, 638
monoamine deficiency corrected via, 1037
β-phenylethylamine-induced seizures prevented by, 999
sleep alterations induced by, 459
thyroid function affected by, 967
with triiodothyronine, against panic disorder, 1061
Antisaccade task
abnormalities in, in schizophrenia, 943
Antisocial personality disorder
with substance abuse, altered serotonergic responsivity in, 325
Anxiety disorders
adrenergic status in, 3
alprazolam against, 849
benzodiazepines against, 1021-ed
carbon dioxide challenge test in, 743
m-chlorophenylpiperazine sensitivity in, 1053
imipramine against, 849
isoproterenol in induction of, 203
Anxiogenic challenge studies
of major depressive disorder, 21
of panic disorder, 21
Appetite
MK-329 effect on, 169
Apraxia
assessment of, 181
Arginine vasopressin
in water intoxication, 829-le
Arousal
caffeine induction of, 35
Ascending noradrenergic bundle
lesion, skin conductance response after, 151
Ascorbic acid
load test, in schizophrenia assessment, 959
Atenolol
in tardive akathisia, 809
Atropine
muscarinic supersensitivity induced by, 609
Attention deficit disorder
event-related potentials in, 879
with hyperactivity, assessment of in children, 193
plasma catecholamine levels in, 547
zinc levels in, 165
Auditory evoked potentials
in attention deficit hyperactivity disorder, 879
of lateralized hemispheric dysfunction, in schizophrenia, 275
in schizophrenia, 435, 819, 1065-le, 1066-le (response)
Autism
biochemical model for, 773
Autoantibodies
against brain septal region antigens, in unmedicated schizophrenia, 467
plasma, to imipramine binding sites, 365
Autoimmune deficiency syndrome (AIDS)
psychosis in, 551-le
Autonomic dysfunction
in porcine stress syndrome, 58

Baboons
adrenocortical function in, 862
personality in, 862
social dominance in, 862

Baclofen
β-phenylethylamine effects reduced by, 997
Basal ganglia
assymetric metabolism over, in catatonia, 177-le
T_2 relaxation time values for, 1027
Behavioral treatment
of obsessive-compulsive disorder, 1072-le, 1073-le (response)
Benzodiazepines
abuse of, in depression, 85
against anxiety, 1021-ed
against catatonia, 178-le, 179-le (response)
against depression, 1021-ed
peripheral binding of, in Alzheimer's disease, 641
β-phenylethylamine effects prevented by, 997
against psychosis, 1021-ed
receptors for, tandospirone activity at, 99
against schizophrenia, 1021-ed
Benztropine
against catatonia, 178-le, 179-le (response)
in tardive akathisia, 809
Bethanechol
in olfactory function, 79
Binaural conditions
story recall under, 794
Bipolar disorder
chromosome markers in, 63
circadian rhythms in, 117
methionine adenosyl transferase activity in, 1049
Blood pressure
alprazolam effect on, 849
in anxiety disorders, 3
caffeine effect on, 35
imipramine effect on, 849
isoproterenol effects on, 203
Borderline personality disorder
cerebrospinal fluid metabolites in, 247
Brain
iron content in, 1028
weight, gender differences in relationship to, 931
Brainstem
auditory-evoked potentials, in schizophrenia, 819
Brief Psychiatric Rating Scale (BPRS)
caffeine in schizophrenia and, 35
one-carbon metabolism changes assessed via, 1049
after psychoactive drug treatment, 215
Bromocriptine
against porcine stress syndrome, 58
Bulimia nervosa
cholecystokinin in, 169
5-hydroxytryptamine in, 644
pituitary gland in, 110
serotonin pathways in, 443
in tardive akathisia, 809
Bunney-Hamberg ratings
caffeine in schizophrenia and, 35
Buprenorphine
psychiatric response to, 1078-le
Buspirone
gepirone as analogue of, 73
neurotransmitter receptor binding by, 99
β-phenylethylamine-induced seizures prevented by, 999
Buspirone/prolactin test
in posttraumatic stress disorder assessment, 665
Butyrylcholinesterase
in Alzheimer's disease, 388

Caffeine
as anxiogen, 997
in schizophrenia, 35
Cancer
depression associated with, 522
Cannabis
abuse, in depression, 85
Captopril
against water intoxication, 829-le
Carbamazepine
triiodothyronine-decreasing effect of, 968
Carbohydrate
craving, in seasonal affective disorder, 989
Carbon dioxide challenge test
high-dose, in anxiety disorder, 743
Cardiovascular response
to imipramine, 849
to pulse unilateral ECT, 758
Catecholamines
in depression, 1037
Cataplexy
canine, prostaglandin E_2 against, 904
HLA-DR2 in, 1012-le
Catatonia
assymetric metabolism over basal ganglia in, 177-le
benzodiazepines against, 178-le, 179-le

(response)
Catecholamines
in aggressive behavior, 247
in anxiety disorders, 3
in hyperactivity, 547
in panic disorder, 292
in porcine stress syndrome, 59
in schizophrenia, 151
in skin conductance response, 151
Catecholestrogens
in endogenous retarded depression, 685
Caudate nucleus
iron content in, 1028
left, T_2 relaxation times in, in tardive dyskinesia, 1027
Central nervous system (CNS)
HIV infection in, as AIDS psychosis cause, 551-le
Cerebrospinal fluid (CSF)
free radical activity, in tardive dyskinesia, 535
metabolites, in Alzheimer's disease, 387
metabolites, in borderline personality disorder, 247
metabolites, intercorrelations among, 595
metabolites, in major depression, 358
metabolites, in schizophrenia, 435
prostaglandin E_2 levels, in canine narcolepsy, 904
protein, elevated in depression, 629
TRH concentrations, in alcoholics, 767
Ceruletide
in cognitive function, 169
Children
comorbidity in interpretation of dexamethasone suppression test results in, 193
hyperactive, event-related potentials in, 879
hyperactive, plasma catecholamines in, 547
hyperactive, zinc levels in, 165
Chlordiazepoxide
β-phenylethylamine-induced seizures prevented by, 999
m-Chlorophenylpiperazine
challenge, in assessment of altered serotonergic responsivity in antisocial personality disorder with substance abuse, 325
in elderly depressed patients, 588
as 5-hydroxytryptamine receptor probe, 358
hypersensitivity to, in panic attacks, 1053
Chlorpromazine
prior to sleep deprivation therapy, 981
Cholecystokinin
receptor antagonist, hunger induced by, 169
Cholinesterase
in Alzheimer's disease, 387
Choreoathetoid movement disorders
diseases of metal metabolism in, 1027
Chromaffin cells
in monoaminergic neural transplantation, 1038
Chromosome 11p15
markers, in unipolar affective disorder, 63
Chromosome 21
band q22, glycinamide ribonucleotide synthetase coded on, 1058
Chromosome Xq
marker, in affective disorder, 63
Cigarette smoking
in haloperidol pharmacokinetics, 529
inverse association between neuroleptic-induced Parkinsonism and, 502
Circadian rhythms
cortisol levels and, 47
in depression relapse after sleep deprivation therapy, 980
lithium effect on, 117
Clomipramine
against obsessive-compulsive disorder, 401, 1072-le, 1073-le (response)
side effects of, 1072-le, 1073-le (response)
sleep alterations induced by, 459
thyroid function affected by, 967
Clonidine
against anxiety disorders, 3
challenge test, abnormal growth hormone response after, 308
β-phenylethylamine-induced seizures prevented by, 999
in tardive akathisia, 809
Cocaine abuse
in depression, 85
hyperprolactinemia in, 824
Cognitive functions
neuroanatomical sexual dimorphism relationship to, 931
Cognitive impairment
in Alzheimer's disease, 372
cholecystokinin in, 169
in late-onset paranoid psychosis, 266
in Wilson's disease, 255
Color blindness
chromosone X28 marker for, 63

Comment
The Effect of Diagnostic Methodology on the Sensitivity of the TRH Stimulation Test for Depression: A Literature Review, 733
A Possible Role of Hippocampal Dysfunction in Schizophrenic Symptomatology, 87
Computed tomography (CT) scanning
in Alzheimer's disease, 388
in panic disorder, 721
prefrontal cortical brain atrophy assessed via, 1023-ed
in primary degenerative dementia, 425
Conflict situation test
anxiogenic effects of β-phenylethylamine assessed via, 997
Copper
deposition, in Wilson's disease, 1027
Corpus callosum
curvature, in schizophrenic twins, 83-le
sexual dimorphism of, 931
Correspondence
Amphetamine and Tranylcypromine in Treatment-Resistant Depression, 1011
Assymetric Metabolism Over Basal Ganglia in Catatonia, 177, 177 (response)
Benzodiazepines and Catatonia, 178, 179 (response)
Buprenorphine Responders, 1078
Corpus Callosum Curvature in Schizophrenic Twins, 83
D_2 Receptor Occupancy and Plasma Concentration of Antipsychotics, 1067, 1068 (response)
Diagnosis of Depression in Alcoholics, 84
Drug Versus Behavioral Treatment of Obsessive-Compulsive Disorder, 1072, 1073 (response)
EPS, NMS, and AIDS, 551
Evoked Response to Repeated Auditory Stimuli, 1065, 1066 (response)
Excitatory Amino Acids and Schizophrenia, 552, 553 (response)
Filter Frequency in P_3 Experiments, 1070, 1071 (response)
HLA-DR2 and Sleep Onset REM Periods in Depression, 1012
Importance of Treatment Follow-Up, 554
Lithium Potentiation of Tricyclic Antidepressants, 1075
Olfactory Sense in Psychoses, 830
Stereotypic Behavior and Hyponatremia, 1077
Water Intoxication Treatment, 829, 829 (response)
Cortex
hyperarousal of, in obsessive-compulsive disorder, 92
prefrontal, in schizophrenia, 1023-ed
Corticotropin-releasing hormone
receptor, in Alzheimer's disease, 603
receptor, in major depression, 603
Cortisol
in antisocial personality disorder with substance abuse, 325
in autism, 773
caffeine effect on, 35
m-chlorophenylpiperazine effect on, 1053
early morning secretion of, 47
gepirone effect on levels of, 73
hypersecretion, in depression relapse, 1007
ipsapirone induction of, 620
in major depressive disorder, 657
after methylphenidate test, 638
nocturnal secretion of, 47
in posttraumatic stress disorder, 657
propofol effect on levels of, 315
during sleep deprivation, in major depressive disorder, 556, 569
urinary-free, in cancer patients with and without depression, 522
urinary-free, prediction of dexamethasone suppression test results in depressives via, 349
yohimbine-induced increase of, in panic disorder, 292

Dark-light chamber
anxiogenic effects of β-phenylethylamine assessed via, 997
Dentate nucleus
iron content in, 1028
Depression
in adolescents, imipramine effect on sleep in, 459
anxiogenic challenge studies of, 21
alcoholism diagnosed in, 84-le
behavioral, 1037
benzodiazepines against, 1021-ed
bipolar, 63
buprenorphine against, 1079-le
cancer associated with, 522

catecholestrogens in, 685
corticotropin-releasing hormone receptor in, 603
cortisol hypersecretion in, 1007
CSF protein elevation in, 629
dexamethasone suppression test in, 193, 349
dopaminergic mechanism of imipramine action in, 223
eating disorders associated with, 443
EEG sleep in, 673
in elderly, *m*-chlorophenylpiperazine against, 588
endogenous retarded, 685
event-related potentials in, 372
frequency distribution of REM sleep timing in, 911
gepirone effect on cortisol levels in, 73
growth hormone response in, 308
HLA-DR2 in, 1012-le
5-HT_2 receptors in, 215
imipramine binding by platelet membranes in, 365
major, 21, 73, 365, 443, 358, 365, 522, 556, 569, 603, 657, 673, 830, 911, 1079-le
manic, 193
methionine adenosyl transferase activity in, 1049
monoaminergic neural transplants against, 1037
olfactory sense in, 830
plasma tetrahydrobiopterin levels in, 526
posttraumatic stress disorder concurrent with, 657
REM latency in, 161, 697
serotonin dysregulation in, 443
sleep deprivation in, 556, 569, 979
thyroid indices in, 967
TRH stimulation test in (comment), 733
unipolar, 620, 1012
in Wilson's disease, 255
Desipramine
methylphenidate test in prediction of therapeutic response to, 638
in monoamine reuptake blockade, 231
after sleep deprivation therapy, 981
thyroid function affected by, 967
Desipramine/growth hormone stimulation test
in posttraumatic stress disorder assessment, 665
Desmethylimipramine
anhednoia reduced by, 224
against obsessive-compulsive disorder, 402
Dexamethasone suppression test
in children, comorbidity in interpretation of, 193
in depression, 349, 1007
in posttraumatic stress disorder, 665, 657
Diabetes
induction, tricyclic antidepressant effect on thyroid function assessed via, 967
Diazepam
β-phenylethylamine effects prevented by, 997
prior to sleep deprivation therapy, 981
Dietary factors
in schizophrenia, 959
N,*N*-Dimethyltryptamine
metabolism of, 841
Dopamine
amineptine effect on, 1004
blocking agents, tardive dyskinesia associated with, 1027
in hyperactivity, 547
in porcine stress syndrome, 59
in prolactin secretion, 824
receptor antagonists, imipramine-induced improvement of depression reversed by, 223
receptor blockade, in neuroleptic malignant syndrome, 58
receptor occupancy, plasma concentration of antipsychotics and, 1067-le, 1068-le (response)
receptors, tandospirone potency at, 99
repetitive behaviors and, 87
in schizophrenia, 435
in skin conductance response, 151
synapses, in imipramine mechanism of action, 223
Dopaminergic systems
caffeine effect on, 35
Down's syndrome
Alzheimer's disease correlated with, 1058
DXS52 marker
on chromosome Xq, in unipolar affective disorder, 63
Dysarthria
in Wilson's disease, 255

Early morning secretion
of ACTH, 47
of cortisol, 47
of hormones in sleep deprivation, 556
Eating disorders
depression associated with, 443
serotonin pathways in, 443

ECT. *See* Electroconvulsive therapy
Editorial
The Annual Meeting of the Society of Biological Psychiatry: President's Message, 929
Drug Trials and Heterogeneity in Schizophrenia: The Mean is not the End, 1021
Getting Away With Murder, 555
The Psychiatric Literature: Some Perspectives, 1
Psychiatry Down Under, 835
The Scope of Biological Psychiatry, 741
Theory and Practice, 649
EEG. *See* Electroencephalogram
Elderly
depression in, *m*-chlorophenylpiperazine against, 588
Electroconvulsive therapy (ECT)
depressive relapse after, prediction of, 1007
5-HT1A receptor desensitization after, 73
methionine adenosyl tranferase activity after, 1049
monoamine deficiency corrected via, 1037
pulse unilateral, cardiovascular response to, 758
seizure duration, propofol reduction of, 315
after sleep deprivation therapy, 981
triiodothyronine-decreasing effect of, 968
Electroencephalogram (EEG)
computerized, in schizophrenia, 488
in panic disorder, 721
sleep, gender effects on in depressives, 673
Electromyographic activity
imipramine effect on, 849
from neck muscles, 1065-le
Electrooculographic potential
from eye movements, 1065-le, 1066-le (response)
Enalapril
against water intoxication, 829-le
β-Endorphin
in autism, 773
Energy regulation
in nonseasonal depressives, 989
in seasonal affective disorder, 989
Epilepsy
prior to panic disorder, 721
schizophrenia-like psychoses in, 127
Epinephrine
alprazolam effect on, 849
plasma, in anxiety disorders, 3
in porcine stress syndrome, 59
Essential fatty acids
metabolism of, zinc role in, 165
Estradiol
in menstrual cycle-related depression, 339
during sleep deprivation, in major depressive disorder, 556
Estrogen
effect of on tritiated imipramine binding sites in surgical menopause, 339
replacement, in postmenopausal disorders, 369-ed
Ethanol
β-phenylethylamine-induced seizures prevented by, 999
Event-related potentials
in Alzheimer's disease, 372
in attention deficit hyperactivity disorder, 879
in depression, 372
endogenous, in obsessive-compulsive disorder, 92
Evoked potentials
of lateralized hemispheric dysfunction, in schizophrenia, 275
Extrapyramidal system
iron content in, 1028
neuroleptic side effects in AIDS and, 551-le
Eye tracking dysfunction
in schizophrenia, 705

Family history
of psychiatric illness, urine MHPG levels in health control subjects correlated with, 174
Fenfluramine
as 5-hydroxytryptamine challenge agent, 358
oral challenge of, in anxiogenic challenge studies, 21
reduced neuroendocrine responses to, suicidal behavior associated with, 247
Fertility
in schizophrenia, 455
Fetus
brain lesions in, in development of schizophrenia, 127
Fine motor function
assessment of, 181
Fluoxetine
in neuroleptic malignant syndrome, 518
sleep alterations induced by, 459
Follicle-stimulating hormone (FSH)
during sleep deprivation, in major depressive disorder, 556

Follow-up
to treatment, importance of, 554-le
Food
deprivation, tricyclic antidepressant effect on thyroid function assessed via, 967
Free radicals
brain, in tardive dyskinesia, 535, 1027

Gamma-aminobutyric acid (GABA)
in aggressive behavior, 247
neurotransmitter system, in tardive dyskinesia, 1027
phenibut as derivative of, 997
Gangliogliomas
in schizophrenia-like psychoses, 127
GBS rating scale
in Alzheimer's disease assessment, 387
Gender differences
in brain weight, 931
in CSF protein levels, 629
in depressive illness, 339
in EEG sleep of depressives, 673
in primary degenerative dementia hormone levels, 144
in seasonal variations of ^{3}H-paroxetine binding to platelets, 509
Generalized anxiety disorder
alprazolam against, 849
imipramine against, 849
Genetic factors
in schizophrenia, 959
Gepirone
5-HT1A agonist properties of, effect of on serum cortisol levels, 73
neurotransmitter receptor binding by, 99
Gliosis
in Alzheimer's disease, 641
Globus pallidus
iron content in, 1028
sterotactic localization in indentification of, 177-le
Glucose-6-phosphate dehydrogenase (G6PD)
chromosome X28 marker for, 63
Glycinamide ribonucleotide synthetase
activity, in Alzheimer's disease, 1058
Growth hormone (GH)
in Alzheimer's disease, 362
response, after clonidine and insulin challenge tests, 308

Hair
zinc levels, in hyperactivity, 165
Hallervorden-Spatz disease
iron deposition in, 1027
Haloperidol
D_2 receptor occupancy and, 1067-le, 1068-le (response)
pharmacokinetics, smoking effect on, 529
β-phenylethylamine effects prevented by, 997
porcine stress syndrome induced via, 58
Halothane
challenge, in induction of porcine stress syndrome, 59
Hamilton Depression Rating Scale (HDRS)
one-carbon metabolism changes assessed via, 1049
scores, after psychoactive drug treatment, 215
Handedness
neuroanatomical sexual dimorphism relationship to, 931
Harm avoidance
in obsessive-compulsive disorder, 41
Hasegawa dementia scale
in Alzheimer's disease assessment, 387
Heart rate
imipramine effect on, 849
Hebephrenia
computerized EEG in, 488
Heroin
addiction, transcutaneous cranial electrostimulation against, 650
Heterogeneity
in schizophrenia, 1021-ed
Hippocampus
lesions of, in chronic schizophrenia, 87
HLA-DR2
in depression, 1012-le
Hoarding
pathogenesis of, 87
Homovanillic acid (HVA)
acid transport blockade and, 595
in Alzheimer's disease, 387
in borderline personality disorder, 247
plasma levels of, yohimbine effect on in panic disorder, 292
in schizophrenia, 435, 1023-ed
HRAS1 marker
on chromosome 11p15, in unipolar affective disorder, 63
Human growth hormone (HGH)

during sleep deprivation, in major depressive disorder, 569
Human immunodeficiency virus (HIV)
CNS infection with, as cause of AIDS psychosis, 551-le
Hunger
induction of by MK-329, 169
Hydrocephalus
corpus callosum abnormalities in, 83-le
5-Hydroxy-*N*,*N*-dimethyltryptamine
metabolism of, 841
6-Hydroxydopamine (6-OHDA)
lesion, of central noradrenaline system, skin conductance response after, 151
2-Hydroxyestrogens
in endogenous retarded depression, 685
5-Hydroxyindoleacetic acid (5-HIAA)
acid transport blockade and, 595
in Alzheimer's disease, 387
in borderline personality disorder, 247
in major depression, 358
in schizophrenia, 435
5-Hydroxytryptamine (5-HT)
in affective disorders, 588
in aggressive behavior, 247
agonist properties, of gepirone, 73
amineptine effect on, 1004
antagonists, sucrose consumption increased by, 223
in antisocial personality disorder with substance abuse, 326
in autism, 773
in depression, 215, 358, 443, 620, 1037
in eating disorders, 443, 644
in obsessive-compulsive disorder, 41
in panic anxiety, 1053
receptor, gepirone affinity for, 73
receptor, tandospirone potency at, 99
in REM sleep regulation, 232
reuptake, blocking of, 231
in suicide, 215
uptake sites, hemispheric distribution of, 544
5-Hydroxytryptophan
as 5-hydroxytryptamine challenge agent, 358
Hyperactivity
event-related potentials in, 879
methylphenidate against, 547
plasma catecholamine levels in, 547
zinc levels in, 165
Hyperarousal
cortical, in obsessive-compulsive disorder, 92
Hyperdopaminergic function
in tardive dyskinesia, 1027
Hyperphagia
in seasonal affective disorder, 989
Hyperprolactinemia
in cocaine abuse, 824
Hypersomnia
in seasonal affective disorder, 989
Hyperthermia
in porcine stress syndrome, 58
Hyperthyroidism
in depression, 967
Hyperventilation
baseline, in panic disorder, 743
Hypoglycemia
induced, in affective illness, 308
Hypomania
after sleep deprivation therapy, 981
Hyponatremia
dilutional, stereotypic behavior with, 1077-le
Hypoprolactinemia
in cocaine abuse, 824
Hyposmia
in Alzheimer's disease, 79
Hypothalamic-pituitary-adrenal (HPA) axis
in Alzheimer's disease, 362
in depression, 349
5-HT1A receptor mediation of, 73, 620
in wild baboons, 862
Hypothalamus
anterior, sexual dimorphism of, 932
in autism, 773
cocaine abuse effects on, 824
in primary degenerative dementia, 144
in regulation of circadian rhythms, 118
Hypothyroidism
in depression, 967

IgG autoantibodies
against brain septal region antigens, in unmedicated schizophrenia, 467
to imipramine binding sites, 365
Imipramine
dopaminergic mechanism of action of, 223
estrogen effect on binding site density of, 339
against generalized anxiety disorder, 849
in major depression, 365
methylphenidate test in prediction of therapeutic response to, 638

in obsessive-compulsive disorder, 41
prior to sleep deprivation therapy, 981
thyroid function altered by, 967
with triiodothyronine, against panic disorder, 1061
Incentive-conditioned behaviors
hippocampal dysfunction in, 87
Indolealkylamines, psychotomimetic
metabolism of, 841
INS marker
on chromosome 11p15, in unipolar affective disorder, 63
Insulin
challenge test, abnormal growth hormone response after, 308
Internal Coincidence model
for depression relapse after sleep deprivation therapy, 980
Ipsapirone
in corticotropin induction, 620
neurotransmitter receptor binding by, 99
Iron
deposition, in Hallervorden-Spatz disease, 1027
metabolism, in tardive dyskinesia, 1027
Isoproterenol
panic attacks induced by, 203

Ketanserin, tritiated
in 5-HT_2 receptor binding, 216
Lactate
intravenous infusion of, in anxiogenic challenge studies, 21
Lateralization of function
neuroanatomical sexual dimorphism relationship to, 931
Lateralized hemispheric dysfunction
in schizophrenia, 275
Learned helplessness paradigm
in assessment of tricyclic antidepressant effect on thyroid function, 967
monoaminergic neural transplants in prevention of, 1037
Left hemisphere
involvement, in obsessive-compulsive disorder, 92
Limoge current
transcutaneous electrostimulation with, 650
^{7}Li nuclear magnetic resonance spectroscopy
lithium concentration in red blood cells assessed via, 415
Lithium carbonate
circadian period altered by, 117
in dampening of muscarinic supersensitivity, 609
porcine stress syndrome induced via, 58
potentiation, of tetracyclic antidepressants, 1075-le
red blood cell transport of, 415
against schizoaffective disorder, 178-le
side effects of, 464-ed
sleep alterations induced by, 459, 981
triiodothyronine-decreasing effect of, 968
against water intoxication, 829-le
Liver
symptoms, in Wilson's disease, 255
toxicity, of amineptine, 1004
Locus ceruleus
firing, yohimbine-induced in panic disorder, 292
Luteinizing hormone (LH)
in Alzheimer's disease, 362
during sleep deprivation, in major depressive disorder, 556
Luteinizing hormone-releasing hormone (LHRH)
in Alzheimer's disease, 362
Lysergic acid diethylamide (LSD)
in 5-HT_2 receptor binding, 215

Macroadenoma
pituitary, in eating disorders, 110
Magnetic resonance imaging (MRI)
corpus callosum abnormalities detected via, 83-le
gender differences in human brain assessed via, 931
globus pallidus assessed via-le, 177
late onset psychosis assessed via, 266
pituitary gland assessed via, 110
tardive dyskinesia assessed via, 1027
Major depressive disorder
anxiogenic challenge studies of, 21
buprenorphine against, 1079-le
cancer associated with, 522
corticotropin-releasing hormone receptor in, 603
EEG sleep in, 673
in elderly, *m*-chlorophenylpiperazine against, 588
gepirone effect on cortisol levels in, 73
frequency distribution of REM sleep timing in, 911
5-hydroxytryptamine receptor sensitivity in, 358

imipramine binding by platelet membranes in, 365
olfactory sense in, 830
posttraumatic stress disorder concurrent with, 657
serotonin dysregulation in, 443
sleep deprivation in, neuroendocrinological investigations and, 556, 569
Manganese
environmental overexposure to, 1027
Mania
as antidepressant side effect, 532
caffeine in, 35
methionine adenosyl transferase activity in, 1049
as phototherapy side effect, 532
Manic depressive disorder
dexamethasone suppression test in assessment of in children, 193
Maprotiline
lithium potentiation of, 1075-le
Massa intermedia
sexual dimorphism of, 932
Melatonin
pineal, in autism, 773
Memory
retention, MK-329 effect on, 169
Memory-saccade task
in schizophrenia assessment, 943
Menopause
surgical, estrogen effect on tritiated imipramine binding site density in, 339
Menstrual cycle
in depression, 339
Metergoline
m-chlorophenylpiperazine effects after administration of, 1053
sucrose consumption increased by, 223
Methamphetamine
in ACTH secretion, 47
in cortisol secretion, 47
Methionine adenosyl transferase
activity, after ECT, 1049
5-Methoxy-*N*,*N*-dimethyltryptamine
metabolism of, 841
2-Methoxyestrogens
in endogenous retarded depression, 685
Methylphenidate
against hyperactivity, 547
test, in tricyclic antidepressant choice, 638
Methysergide
m-chlorophenylpiperazine effects after administration of, 1053
Metoclopramide
in tardive akathisia, 809
Metoprolol
in tardive akathisia, 809
MHPG
acid transport blockade and, 595
in Alzheimer's disease, 388
in borderline personality disorder, 247
urinary, psychiatric family history of healthy control subjects correlated with, 174
yohimbine-induced increase of in panic disorder, 292
Mianserin
lithium potentiation of, 1075-le
MK-329
hunger induced by, 169
Monoamine
metabolites, in Alzheimer's disease, 387
metabolites, correlations among, 595
reuptake blockade, REM sleep suppression by, 231
Monoamine oxidase (MAO) inhibitors
against endogenous retarded depression, 685
monoamine deficiency corrected via, 1037
sleep alterations induced by, 459
psychostimulant coadministration with, 1011-le
Monoaminergic neural transplants
against behavioral depression, 1037
Monoaural assymetry
in story recall, 794
Morphine
analgesia, transcutaneous electrostimulation in potentiation of, 650
MRI. *See* Magnetic resonance imaging
Multi-infarct dementia
discrimination of from Alzheimer's disease, 641
Murder
biochemical basis of, 555-ed
Muscarinic cholinergic receptors
tandospirone activity at, 99
Muscarinic phosphoinositide response
atropine-induced supersensitivity of, prevention of, 609
Muscle
rigidity, in porcine stress syndrome, 58
tension, imipramine effect on, 849

N200 latencies
in obsessive-compulsive disorder, 92
Narcolepsy
canine, CSF prostaglandin E_2 in, 904
HLA-DR2 in, 1012-le
Neocortex
frontal, monoaminergic neural transplants in, 1037
Neural transplants
monoaminergic, against behavioral depression, 1037
Neurochemical factors
in schizophrenia, 959
Neurofibrillary tangles
in Alzheimer's disease, 387
Neuroleptic malignant syndrome
in AIDS, 551-le
fluoxetine in, 518
porcine stress syndrome as model for, 58
Neuroleptics
akathisia induced by, 809
effect of on platelet polyphosphoinositide system in schizophrenia, 475
parkinsonism induced by, 502
in tardive dyskinesia, 1027
Neurological signs
in schizophrenia, 181
Neurophysin
neurohypophyseal, posterior lobe hypersensitivity of pituitary gland caused by, 111
Neurotransmitters
caffeine effect on, 35
in obsessive-compulsive disorder, 41
receptor binding sites for, tandospirone interaction with, 99
Nocturnal secretion
of ACTH, 47
of cortisol, 47
Nonlocalizing signs
assessment of, 181
Norepinephrine
alprazolam effect on, 849
in anxiety disorders, 3
in depression, 1037
imipramine effect on, 849
in porcine stress syndrome, 59
reuptake, blocking of, 231
in skin conductance response, 151
yohimbine-induced release of in panic disorder, 292
Nortriptyline
methylphenidate test in prediction of therapeutic response to, 638
with triiodothyronine, against panic disorder, 1061
No-saccade task
in schizophrenia assessment, 943
Nucleus accumbens
dysfunction of, in schizophrenia, 87
(–)sulpiride activity in, 297

Obsessive-compulsive disorder
behavioral treatment of, 1072-le, 1073-le (response)
clomipramine against, 401, 1072-le, 1073-le (response)
desmethylimipramine against, 402
endogenous event-related potentials in, 92
tridimensional personality theory in, 41
Oddball task
auditory, event-related potentials assessed via, 92
Olfaction
neurochemistry of, 79
in psychosis, 830-le
One-carbon system alterations
in major psychiatric disorders, 1049
Opiate abstinence syndrome
transcutaneous electrostimulation in attenuation of, 650
Opiates
abuse of, in depression, 85
Opioid peptides
in autism, 773
cells containing, transplantation of, 1038
Oxazepam
β-phenylethylamine-induced seizures prevented by, 999

P_3 experiments
filter frequency in, 1070-le, 1071-le (response)
P3b intrachannel selection mechanisms
in attention deficit hyperactivity, 879
P50 wave
in evoked response to repeated auditory stimuli, 1065-le, 1066-le (response)
P300 latency
in Alzheimer's disease, 372
in depression, 372
in obsessive-compulsive disorder, 92

Pacing
pathogenesis of, 87
Panic disorder
adrenergin status in, 3
anxiogenic challenge studies of, 21
buprenorphine against, 1079-le
carbon dioxide challenge test in, 743
m-chlorophenylpiperazine sensitivity in, 1053
CT scanning in, 721
EEG in, 721
isoproterenol in induction of, 203
triiodothyronine with tricyclic antidepressants against, 1061
yohimbine effect on plasma homovanillic acid levels in, 292
Papio anubis
adrenocortical function in, 863
personality in, 863
social dominance in, 863
Paranoid psychosis
late-onset, cerebral white matter disease in, 266
Parietal function
assessment of, 181
Parkinsonism
neuroleptic-induced, inverse association between smoking and, 502
Paroxetine
tritiated, seasonal variations in binding of to platelets, 509
tritiated, symmetrical hemispheric distribution of, 544
Pentylenetetrazole
as anxiogen, 997
PET. *See* Positron emission tomography
Phenazepam
β-phenylethylamine-induced seizures prevented by, 999
Phenibut
mode of action of, 997
β-phenylethylamine effects reduced by, 997
β-Phenylethylamine
as endogenous anxiogen, 997
Phenytoin
against water intoxication, 829-le
Phospholipase A_2
serum, in schizophrenia, 495
Phobia
social, carbon dioxide challenge test in, 743
Phototherapy
against depression, 117
effect of on resting metabolic rate in seasonal affective disorder, 989
mania as side effect of, 532
Physostigmine
in tardive akathisia, 809
Pimozide
imipramine-induced improvement of depression reversed by, 223
Pineal gland
in autism, 773
tissue, in monoaminergic neural transplantation, 1037
Pituitary gland
in eating disorders, 110
Plasma
autoantibodies, to imipramine binding sites, 365
catecholamines, in hyperactive children, 547
homovanillic acid, in schizophrenia, 1023-ed
tetrahydrobiopterin, in affective disorders, 526
vitamin C, in schizophrenia, 959
Platelet
benzodiazepine binding, in Alzheimer's disease, 641
membranes, paroxetine binding to, 509
polyphosphoinositide system, in schizophrenia, 475
Polydipsia
pathogenesis of, 87
in schizophrenia, 1077-le
Polygraphy
sleep, in schizophrenia, 240
Porcine stress syndrome
as animal model for neuroleptic malignant syndrome, 58
Positive and Negative Syndrome Scale
in assessment of chronic schizophrenia, 181
Positive-negative dimension
in schizophrenia, 181
Positron emission tomography (PET)
globus pallidus assessed via, 177-le
Postmenopause
estrogen replacement in, 369-ed
Postprandial deactivation syndrome
exogenous cholecystokinin in, 169
Posttraumatic stress disorder (PTSD)
buprenorphine against, 1079-le
dexamethasone suppression test in, 657
neuroendocrine test battery in, 665
TRH stimulation test in, 657

Preeclampsia
zinc deficiency in, 165
Prefrontal deficit
negative syndrome in schizophrenia related to, 181
Pregnancy
zinc deficiency in, 165
Primary degenerative dementia
CT scanning of, 425
prolactin in, 144
thyrotropin-stimulating hormone in, 144
Probenecid
in acid transport blockade, 595
Profile of Mood (POM) Scale
buprenorphine response assessed via, 1080-le
Progesterone
in menstrual cycle-related depression, 339
Prolactin
in Alzheimer's disease, 362
in antisocial personality disorder with substance abuse, 325
m-chlorophenylpiperazine effect on, 1053
in cocaine abuse, 824
in primary degenerative dementia, 144
response in electroconvulsive therapy, propofol effect on, 315
during sleep deprivation, in major depressive disorder, 556, 569
Prolixin
oxidative stress induced by, 738
Proopiomelanocortin
peptides, in autism, 773
Propofol
effect of on hormonal response to electroconvulsive therapy, 315
Propranolol
β-phenylethylamine-induced seizures prevented by, 999
prior to sleep deprivation therapy, 981
in tardive akathisia, 809
Prostaglandin E_2 (PGE_2)
in canine narcolepsy, 904
Prostaglandins
formation of, zinc deficiency in, 165
Protein
CSF, elevated in depression, 629
Protirelin
in thyrotropin-releasing hormone stimulation testing, 144
Psychosis
in AIDS, 551-le
amineptine-induced, 1004
benzodiazepines against, 1021-ed
caffeine in, 35
depression associated with, REM latency in, 161
late-onset, cerebral white matter disease in, 266
olfactory sense in, 830-le
schizophrenia-like, in temporal lobe epilepsy, 127
sleep polygraphic measurements skewed by, 240
story recall in, 794
Psychostimulants
MAO inhibitor coadministration with, 1011-le
Pulse
in anxiety disorders, 3
caffeine effect on, 35
Putamen
iron content in, 1028
Pyrimidinylpiperazines
pharmacological effect of, 99

Raclopride
imipramine-induced improvement of depression reversed by, 223
Red blood cells
lithium transaport in, 415
Red nucleus
iron content in, 1028
Reflexive saccades
in schizophrenia, 943
Relapse
cortisol hypersecretion predictive of for depression, 1007
in sleep deprivation therapy against depression, 979
REM latency
in psychotically depressed adolescents, 161
in schizophrenia, 240
REM sleep
in depressed adolecents, imipramine effects on, 459
in depression, 697
in EEG sleep of depressives, 673
frequency distribution, in major depression, 911
HLA-DR2 and, 1012-le
short latency to onset of, circadian rhythm effect on, 117
supression, by monoamine reuptake blockade, 231

Repetitive behaviors
hippocampal dysfunction in, 87
Resting metabolic rate
in seasonal affective disorder, 989
Restriction fragment length polymorphisms (RFLPs)
in unipolar affective disorder, 63

Saccadic eye movements
voluntary, in schizophrenia, 943
Saimiri sciureus
lithium effect on circadian period in, 117
SCH-23390
effect of on consumption of sweet solutions, 224
Schedule-induced behavior
hippocampal dysfunction in, 87
Schizophrenia
age of onset for, 455
alprazolam against, 1023-ed
auditory evoked potentials in, 435, 819, 1065-le, 1066-le (response)
benzodiazepines against, 1021-ed
buprenorphine against, 1079-le
computerized EEG in, 488
corpus callosum curvature in, 83-le
drug trials and heterogeneity in, 1021-ed
excitatory amino acids in, 552-le, 553-le (response)
fertility in, 455
globus pallidus in, 177-le
hippocampal dysfunction in, 87
homovanillic acid levels in, 435
5-hydroxyindoleacetic acid levels in, 435
hyponatremia in, 1077-le
lateralized hemispheric dysfunction in, 275
-like psychoses, in temporal lobe epilepsy, 127
methionine adenosyl transferase activity in, 1049
negative symptoms in, 181
neurological signs in, 181
olfactory sense in, 830
platelet polyphosphoinositide system in, 475
polydipsia in, 1077-le
psychosis in conjunction with, 266, 794
saccadic eye movements in, 943
serum phospholipase A_2 activity in, 495
skin conductance response absence in, 151
sleep polygraphy in, 240
smooth pursuit eye movements in, 705, 943
story recall in, 794
tardive dyskinesia with, 1027
unmedicated, autoantibodies against brain septal region antigens specific to, 467
vitamin C status in, 959
Seasonal affective disorder (SAD)
bright light effect on resting metabolic rate in, 989
phototherapy against, 532
Seasonal variations
in ^{3}H-paroxetine binding to platelets, 509
Scopalamine
in olfactory function, 79
Seizures
clonic, β-phenylethylamine-induced, 997
electroconvulsive therapy-induced, propofol reduction of, 315
Sella turcica
in eating disorders, 110
Senile plaques
in Alzheimer's disease, 387
Serotonin. *See* 5-Hydroxytryptamine
Sertraline
in monoamine reuptake blockade, 231
Serum
phospholipase A_2 activity, in schizophrenia, 495
zinc levels, in hyperactivity, 165
Sexual dymorphism
neocortical, in human brain, 931
Simple saccade task
in schizophrenia assessment, 943
Skin conductance response
after 6-hydroxydopamine lession, 151
Sleep
deprivation, in depression, 556, 979
polygraphy, in schizophrenia, 240
Sleep-wake regulation
prostaglandins in, 904
SM-3997. *See* Tandospirone
Smooth pursuit eye movements
saccadic, in schizophrenia, 705, 943
Social phobia
carbon dioxide challenge test in, 743
Sodium hydroxybutryrate
β-phenylethylamine-induced seizures prevented by, 999
Somatostatin
deficiency, in primary degenerative dementia, 144
Stereotactic localization
in identification of globus pallidus, 177-le

Stereotypies
hyponatremia with, 1077-le
pathogenesis of, 87
Steroids
in endogenous retarded depression, 685
gonadal, in brain development, 931
Story recall
in psychiatric patients, 794
Substantia nigra
iron content in, 1028
Suicidal behavior
5-hydroxyindoleacetic acid levels aand, 247
Suicide
5-HT_2 receptors in, 215
(-)Sulpiride
effect of on consumption of sweet solutions, 224
suppression of conditioned avoidance behavior induced by, 297
Switch process
in antidepressant side effects, 532

T_2 relaxation times
left caudate, in tardive dyskinesia, 1027
Tandospirone (SM-3997)
interaction, with neurotransmitter receptor binding sites, 99
Tardive akathisia
pharmacological characterization of, 809
Tardive dyskinesia
in brain production of cytotoxic free radicals, 535
magnetic resonance imaging in, 1027
sleep polygraphic measurements skewed by, 240
tardive akathisia pathophysiology in relation to, 809
vitamin E against, 535
Teciptiline
lithium potentiation of, 1075-le
Temporal lobe
epilepsy, prior to panic disorder, 721
epilepsy, schizophrenia-like psychoses in, 127
Testosterone
during sleep deprivation, in major depressive disorder, 556
Tetracyclic antidepressants
lithium potentiation of, 1075-le
Tetrahydrobiopterin
plasma, in affective disorders, 526
Thiopentone
anestheia, electroconvulsive therapy during, 315
Thiothixene
against schizoaffective disorder, 178-le
Thyroid
function, tricyclic antidepressant effect on, 967
Thyrotropin
during sleep deprivation, in major depressive disorder, 556, 569
tricyclic antidepressant effect on, 967
Thyrotropin-releasing hormone (TRH)
in alcoholics, CSF levels of, 767
stimulation test, in Alzhemimer's disease, 362
stimulation test, in posttraumatic stress disorder, 657
stimulation test, in primary degenerative dementia, 144
stimulation test, sensitivity of in depression (comment), 733
Thyrotropin-stimulating hormone (TSH)
in Alzheimer's disease, 362
in primary degenerative dementia, 144
tricyclic antidepressant effect on, 967
Thyroxine (T_4)
during sleep deprivation, in major depressive disorder, 556, 569
Transcutaneous cranial electrostimulation
in management of opiate abstinence syndrome, 650
Tranylcypromine
amphetamine coadministration with, 1011-le
against endogenous retarded depression, 685
Tricyclic antidepressants
dopaminergic mechanism of action of, 223
isoproterenol infusion after, 203
methylphenidate test in prediction of therapeutic response to, 638
monoamine deficiency corrected via, 1037
β-phenylethylamine-induced seizures prevented by, 999
sleep alterations induced by, 459
thyroid function affected by, 967
with triiodothyronine, against panic disorder, 1061
Tridimensional Personality Questionnaire
in obsessive-compulsive disorder, 41
Triiodothyronine (T_3)
during sleep deprivation, in major depressive disorder, 556, 569
tricyclic antidepressants with, 967, 1061
Tryptamine
as 5-hydroxytryptamine challenge agent, 358

Tryptophan
in treatment of aggressive behavior, 728
Twins
monozygotic schizoprenic, corpus callosum abnormalities in, 83-le

Unipolar depression
chromosome markers in, 63
HLA-DR2 in, 1012-le
Unipolar depression
5-HT1A receptor responsivity in, 620
Urine
MHPG in, psychiatric family history of healthy control subjects correlated with, 174
vitamin C in, in schizophrenia, 959

Vasopressin
neurohypophyseal, posterior lobe hypersensitivity of pituitary gland caused by, 111
Ventral striatum
(-) sulpiride application into, in suppression of conditioned avoidance behavior, 297
Ventriculomegaly
in schizophrenia, 83-le
Violent behavior
5-hydroxyindoleacetic acid levels and, 247
Visual evoked potentials
of lateralized hemispheric dysfunction, in schizophrenia, 275
Visual tracking
in schizophrenia, 705
Vitamin C
status, in schizophrenia, 959
Vitamin E
against tardive dyskinesia, 535

Water
intoxication, hyponatremia and, 1077-le
intoxication, treatment of, 829-le
Wechsler Adult Intelligence Scale (WAIS)
in Alzheimer's disease assessment, 387
Weight
brain, gender differences in relationship to, 931
gain, in seasonal affective disorder, 989
White matter
cerebral, disease of in late-onset paranoid psychosis, 266
Wilson's disease
copper deposition in, 1027
psychiatric symptoms in, 255
Withdrawal
behavioral, in seasonal affective disorder, 989

Yohimbine
as anxiogen, 3, 997
effect of on plasma homovanillic acid levels, in panic disorder, 292

Zinc
levels in hyperactivity, 165